Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

vinkush1 May. 30 at 2:54 AM

$IGC in w a small position will add if needed

0 · Reply

RocketQueen May. 30 at 2:20 AM

$IGC running dual headers with IGC-AD1 and TGR-63 products.

0 · Reply

RocketQueen May. 29 at 3:46 AM

$IGC two horses in the race...

1 · Reply

NewsAndFilings May. 27 at 7:06 PM

$IGC $JAZZ Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification https://www.reuters.com/legal/litigation/companies-with-cannabis-based-drugs-eye-ipos-private-funding-boost-after-us-2026-04-30/

0 · Reply

RocketQueen May. 27 at 3:01 PM

$IGC average PTs over 4.00 USD

0 · Reply

angel6 May. 24 at 2:21 PM

$IGC does anyone know when the trials of IGC-AD1 will come to an end? It has been going on long enough Now they’re running through cash and loosing more money then last year

1 · Reply

MsGrumpy May. 22 at 6:17 PM

$IGC IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-reports-first-quarter-2026-financial-results-with-calma-phase-2-in-the-fin-1168386

0 · Reply

NewsAndFilings May. 22 at 4:36 PM

0 · Reply

MoneyyTalks May. 22 at 1:01 PM

$IGC scam move

0 · Reply

RocketQueen May. 22 at 11:30 AM

$IGC why up over 20% in premie?

1 · Reply

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

2026-05-15T13:00:12.000Z - 15 days ago

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

May 15, 2026, 8:00 AM EDT - 15 days ago

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

May 15, 2026, 8:00 AM EDT - 15 days ago

IGC Pharma Quarterly report: Q1 2026

Apr 28, 2026, 12:15 PM EDT - 4 weeks ago

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

2026-04-22T13:29:55.000Z - 5 weeks ago

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

Apr 22, 2026, 8:30 AM EDT - 5 weeks ago

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

2026-04-20T14:17:51.000Z - 5 weeks ago

IGC Pharma secures Colombian authorization for psilocybin research

Apr 20, 2026, 8:30 AM EDT - 5 weeks ago

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

2026-04-14T12:36:26.000Z - 6 weeks ago

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 8, 2026, 12:45 PM EDT - 7 weeks ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

2026-04-07T12:50:45.000Z - 7 weeks ago

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

Apr 7, 2026, 8:00 AM EDT - 7 weeks ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

2026-03-30T12:38:30.000Z - 2 months ago

IGC Pharma enters national media partnership with New to The Street

Mar 30, 2026, 8:00 AM EDT - 2 months ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

2026-03-25T12:20:15.000Z - 2 months ago

IGC Pharma, New to The Street launch 12-part national media partnership

2026-03-19T13:12:05.000Z - 2 months ago

IGC Pharma reports 9-month revenue $969K

Mar 19, 2026, 9:00 AM EDT - 2 months ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

2026-03-18T13:10:59.000Z - 2 months ago

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

Mar 18, 2026, 9:00 AM EDT - 2 months ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

2026-02-26T13:49:48.000Z - 3 months ago

IGC Pharma files utility patent applications covering AHA framework

Feb 26, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 24, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

2026-02-23T13:49:20.000Z - 3 months ago

IGC Pharma expands Phase 2 CALMA trial with new clinical site

Feb 23, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 18, 2026, 1:00 PM EST - 3 months ago

IGC Pharma Transcript: Status update

2026-02-17T13:52:12.000Z - 3 months ago

IGC Pharma issued notice of allowance by CIPO for IGC-AD1

Feb 17, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 12, 2026, 8:30 AM EST - 3 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 10, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

2026-02-09T14:01:42.000Z - 3 months ago

IGC Pharma expands Phase 2 CALMA trial with new clinical site

Feb 9, 2026, 8:30 AM EST - 3 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

2026-02-02T14:01:51.000Z - 4 months ago

IGC Pharma reaches 70% enrollment in Phase 2 CALMA trial of IGC-AD1

Feb 2, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Jan 22, 2026, 9:00 AM EST - 4 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 12, 2026, 9:00 AM EST - 4 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 6, 2026, 8:00 AM EST - 5 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 5, 2026, 9:00 AM EST - 5 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Dec 19, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 3, 2025, 7:00 AM EST - 6 months ago

IGC Pharma Registration statement: Registration Filing

Dec 2, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 11:00 AM EST - 6 months ago

IGC Pharma Earnings Call Transcript: Q2 2026

Nov 17, 2025, 11:00 AM EST - 6 months ago

IGC Pharma Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 7:00 AM EST - 6 months ago

IGC Pharma Registration statement: Registration Filing

Nov 13, 2025, 9:00 AM EST - 7 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 7 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 7 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 8 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 25, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 19, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 19, 2025, 8:00 AM EDT - 10 months ago

IGC Pharma Proxy statement: Proxy Filing

Aug 18, 2025, 8:00 AM EDT - 10 months ago

IGC Pharma Proxy statement: Proxy Filing

Aug 14, 2025, 4:00 PM EDT - 10 months ago

IGC Pharma Quarterly report: Q2 2025

Aug 12, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Aug 4, 2025, 8:00 AM EDT - 10 months ago

IGC Pharma Proxy statement: Proxy Filing

Jul 23, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

vinkush1 May. 30 at 2:54 AM

$IGC in w a small position will add if needed

0 · Reply

RocketQueen May. 30 at 2:20 AM

$IGC running dual headers with IGC-AD1 and TGR-63 products.

0 · Reply

RocketQueen May. 29 at 3:46 AM

$IGC two horses in the race...

1 · Reply

NewsAndFilings May. 27 at 7:06 PM

0 · Reply

RocketQueen May. 27 at 3:01 PM

$IGC average PTs over 4.00 USD

0 · Reply

angel6 May. 24 at 2:21 PM

$IGC does anyone know when the trials of IGC-AD1 will come to an end? It has been going on long enough Now they’re running through cash and loosing more money then last year

1 · Reply

MsGrumpy May. 22 at 6:17 PM

0 · Reply

NewsAndFilings May. 22 at 4:36 PM

0 · Reply

MoneyyTalks May. 22 at 1:01 PM

$IGC scam move

0 · Reply

RocketQueen May. 22 at 11:30 AM

$IGC why up over 20% in premie?

1 · Reply

MoneyyTalks May. 22 at 8:19 AM

$IGC no volume

0 · Reply

CarlSpagler May. 22 at 2:11 AM

$IGC what happened ?

0 · Reply

RocketQueen May. 21 at 3:19 PM

$IGC double beat at ER.

0 · Reply

CatHerder69 May. 20 at 4:14 PM

$IGC

0 · Reply

LargeNCharge4487 May. 19 at 11:52 PM

$IGC I’m hard right now.

0 · Reply

d_risk May. 19 at 4:50 PM

$IGC - IGC Pharma, Inc. - 10Q - Updated Risk Factors IGC now centers its risk profile on Alzheimer’s drug IGC-AD1 and the Phase 2 CALMA trial, warning that delays, poor or inconclusive data, shifting timelines, regulatory and funding pressures, AI tool limits, intense competition, and macro shocks could each derail its lead program and overall prospects. 🟢 Added 🟠 Removed https://d-risk.ai/IGC/10-Q/2026-05-15

0 · Reply

d_risk May. 19 at 4:40 PM

0 · Reply

IGC May. 19 at 3:32 PM

$IGC New Tau-PET biomarker research by IGC Pharma was presented at the 2026 Global Tau Conference. The poster, titled “Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer’s Disease Progression in Amyloid-Positive APOE4 Carriers,” evaluated whether Shannon entropy can quantify spatial heterogeneity in tau pathology and may help predict future tau accumulation using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). This work aligns with IGC Pharma’s broader strategy of integrating advanced analytics, neuroimaging, and AI-driven approaches to strengthen its Alzheimer’s research platform alongside the ongoing Phase 2 CALMA clinical trial. Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-present-tau-pet-120000503.html . . . #AlzheimersDisease #Neuroimaging #AIinHealthcare #IGCPharma

0 · Reply

OfficialStocktwitsUser May. 18 at 6:57 PM

$IGC RSI: 30.40, MACD: -0.0025 Vol: 0.02, MA20: 0.32, MA50: 0.30 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MrTicker May. 15 at 1:04 PM

$IGC IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference ACCESS NEWSWIRE 7:00 AM ET 5/15/2026

0 · Reply

focafoca99 May. 15 at 12:23 PM

$IGC debuts Tau-PET biomarker research at the 2026 Global Tau Conference. https://www.rapidticker.com/news/igc-igc-pharma-to-present-tau-ef8a82

0 · Reply

mickey1234 May. 12 at 12:50 PM

$IGC buy a little each day while it low before 100% completion date

0 · Reply

Market Cap	29.00M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.15

Volume	262,800
Avg Vol	1,351,720
Day's Range	N/A - N/A
Shares Out	100.09M
Stochastic %K	51%
Beta	0.50
Analysts	Sell
Price Target	$4.12